Recapping the latest Healthcare Fundings

NEWS

Retro Biosciences, a San Francisco startup, is seeking a $1 billion Series A funding round. Founded four years ago, the company develops drugs and therapies for aging-related diseases, including Alzheimer's treatments, blood rejuvenation, and cellular reprogramming to reverse aging. Sam Altman initially funded the company's $180 million seed round and is reportedly considering additional investment.

Maze Therapeutics, a seven-year-old South San Francisco startup developing small-molecule treatments for chronic kidney diseases, has filed an SEC filing for its IPO. The company has raised almost $500 million from venture funds such as Frazier Life Sciences and Deep Track Capital.

Hydreight Technologies (TSXV:NURS, OTCQB:HYDTF), a Vancouver, BC, Canada-based mobile clinical network and medical platform, and VSDHOne, its innovative telehealth and e-commerce platform developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), announced the launch of a D2C Digital Health Accelerator program.

UnitedHealthcare has confirmed that the ransomware attack on its Change Healthcare unit last February affected around 190 million people in America — nearly double previous estimates.

FUNDING

Neko Health, a preventative healthcare technology company based in Stockholm, Sweden, raised $260M in Series B funding. Lightspeed led the round, including General Catalyst, O.G. Venture Partners, Rosello, Lakestar, and Atomico.

Atalanta Therapeutics, a Boston, MA-based company developing RNA interference (RNAi) to treat neurological diseases, raised $75M in Series B funding. The round was led by EQT Life Sciences, co-led by Sanofi Ventures, with participation from other new investors, such as RiverVest Venture Partners, abrdn, Mirae Asset Financial Group, and existing investor F-Prime Capital. The Series B financing brings Atalanta’s total capital generated to date from financings and partnerships with Genentech and Biogen to?USD 240M. The company intends to use the funds to support Phase 1 clinical trials of its investigational?RNAi therapies for KCNT1-related?epilepsy and?Huntington’s?disease.

Eleos, a Boston, MA-based company specializing in AI for behavioral health, raised $60M in Series C Funding. The round, which brought the total amount to $120M, was led by Greenfield Partners. Existing investors, such as F-Prime Capital, Eight Roads, Menlo Ventures, and ION, participated, as did new ones, including the Michael & Susan Dell Foundation, Union Tech Ventures, and Centerstone.

Lindus Health, a NYC-based company that enables customers to run clinical trials, raised?$55M?in Series B funding. The round was led by new investor?Balderton Capital, with support from?Visionaries Club?and existing investors Creandum, firstminute capital, and Seedcamp.

Quibim, a Valencia, Spain-based healthtech company for precision medicine, raised $50M in funding. The round was led by Asabys Partners (through its fund Sabadell Asabys II) and Buenavista Equity Partners (formerly GED Capital) Equity Partners (through the BHG I fund, created in partnership with Columbus Venture Partners), and joined by UI Investissements, and GoHub Ventures as new investors. It was also joined by current investors, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early growth fund) and Tony Fadell’s Build Collective, and individual investor Dr. Jonathan Milner, founder of Abcam plc.??

Amplitude Vascular Systems?(AVS), a Boston, MA-based medical device company, raised $36M in Series B Funding. Backers were not disclosed.

Hone Health, a NYC-based online clinic that provides preventative and proactive longevity care, raised $33M in Series A funding. Backers included Tribe Capital, Public Investment Fund (PIF), Republic Capital, Vibe VC, humbition, Hanwha, Gaingels, Looking Glass Capital, FJ Labs, and Agent Capital, as well as angels including Codie Sanchez, Paul and Michael Rabil, Mark Wan and Matt Wan, Anthony Pompliano, Austin Reif, Shaan Puri, Sam Parr, Nikita Bier, and Fasha Majoor.

Lutris Pharma, a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, raised $30M in funding. The round was led by COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U., and Pontifax Venture Capital, with participation from an existing investor, Peregrine Ventures, and aMoon Fund. The company intends to use the funds to advance the development of LUT014, an innovative topically applied gel to reduce EGFRi-induced rashes, a common adverse side effect of these cancer-fighting therapies.

Elucent Medical Inc., a medical technology company based in Eden Prairie, MN, received $30M in Growth financing from Trinity Capital.

Arctic Therapeutics, a drug discovery and development company based in Reykjavik, Iceland, raised €26.5M in Series A funding. Backers included EIC Fund, Kaldbakur, Sanos Group, Cerebrum DAO, The Lurie Family Foundation, as well as a consortium led by early investors and co-founders of Icelandic unicorns such as Kerecis and Chemometec. Icelandic institutional investors and family offices also participated. The company intends to use the funds to explore the potential of AT-001, an oral treatment designed to prevent the aggregation of harmful amyloid proteins in the brain, in other forms of familial dementia, and eventually Alzheimer’s disease. It will also aim to launch a phase IIa clinical trial for AT-004 in Europe post-financing.

Allara Health, a NYC-based virtual care platform that bridges the care divide for women battling chronic hormonal conditions, raised $26m in Series B funding. The round, which brought the total funding to $38.5m, was led by?Index Ventures, with participation from existing investor?GV (Google Ventures).

Oncomatryx Biopharma, a Zamudio, Spain-based biopharmaceutical company developing novel ADCs against the tumor microenvironment, raised €25M in funding. The round was led by existing investors and included a €10M strategic investment from?Centro para el Desarrollo Tecnológico y la Innovación.

Manas AI, a New York startup co-founded this year by?Reid Hoffman?and?Dr. Siddhartha Mukherjee, is using AI to speed up the discovery and development of new medicines. It focuses initially on aggressive cancers like breast, prostate, and lymphoma. Manas AI raised a $24.6 million round co-led by Hoffman?and?General Catalyst, with?Greylock?participating.

Percipio Health, a population health monitoring and management platform based in Dallas, TX, raised $20M in funding. Backers included?UPMC Enterprises, Wave Ventures, Labcorp, and First Trust Capital Partners.

Commit Biologics, a company based in Aarhus, Denmark, specializing in activating the complement system to treat cancer and autoimmune disease, raised €5.5M in Seed extension funding. The round included the contribution from new investor Korys, bringing the total amount to € 21.5 M.

PinkDx, Inc., a Daly City, CA-based early-stage company focused on positively impacting women's health throughout their life journey, raised $5M in additional Series A funding. Backers included new investors such as The Blue Venture Fund, Sandbox Clinical Ventures, and BEVC. The company intends to use the funds to advance further its first test, which is intended to clarify diagnosis for women presenting with potential gynecologic cancer.

Aligned Marketplace, a NYC-based primary care marketplace for self-insured employers, raised an additional $3M in Seed funding. The round was led by A* and?Maverick Ventures. The company?is a primary care marketplace for self-insured employers that focuses on delivering patient-centered care that empowers prevention, early intervention, and the management of chronic conditions. The marketplace now provides access in all 50 states, with 3,000 clinics within driving distance of over 80 percent of the U.S. population. Contracts with advanced primary care providers, including CirrusMD, Galileo, Summer Health, and more, have strengthened the ecosystem and improved member coverage.?The announcement followed Aligned Marketplace's recent success, including its initial $8M seed funding round and official company launch.?

ExSURE PVT. LTD., a biotech startup based in Bhubaneswar, India, which reduces anticancer drug's side effects and toxicity, raised Rs 3 Cr in Seed Funding. Unicorn India Ventures led the round.

Systole Health, a Boston, MA-based tech-enabled group virtual care solution for women’s heart health, announced $2M in pre-seed funding. Benchstrength led the round, which included participation from January Ventures, J Ventures, and Tom X. Lee, founder of One Medical.

IntelliProve, a health monitoring company based in Ghent, Belgium, raised €1.25 million in funding. Backers included?Miles Ahead?as well as tech entrepreneurs Jeroen De Wit (Teamleader), Louis Jonckheere (Showpad, Wintercircus), Gilles Mattelin and Jorn Vanysacker (Henchman, Intuo), Matthias Geeroms (Lighthouse), and Joris Van Der Gucht (Silverfin). Existing investors include The White and Yellow Cross (Dutch: Wit-Gele Kruis) and the imec.istart fund, with business angels also participating in the financing round.

Sen-Jam Pharmaceutical, a NYC-based company specializing in solutions targeting inflammation and metabolic health, received an investment from 5 Horizons Capital, LLC. The amount of the deal was not disclosed.

Vessl Prosthetics Inc., a startup based in London, Ontario, Canada, specializing in advanced prosthetic systems, raised an undisclosed amount in pre-seed funding.